Table 1.
Clinical characteristics of patients with autoimmune inflammatory rheumatic disease after SARS‐CoV‐2 vaccination
| Age | Sex | Vaccine type |
Time (days) after vaccination |
Clinical manifestations |
ESR (mm/h) |
CRP (mg/dl) |
Significant laboratory findings |
Prognosis | |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 60s | F |
ChAdOx1‐S AstraZeneca (second dose) |
10 days |
Inflammatory polyarthritis (seropositive RA) |
76 | 8.5 |
ANA−, RF 378 IU/ml, anti‐CCP Ab 669 U/ml |
Improved after low‐dose GC, MTX, SSZ, and HCQ |
| Case 2 | 30s | M |
mRNA‐1273 Moderna (first dose) |
4 days |
Migratory inflammatory arthritis (Palindromic rheumatism) |
75 | 10.0 |
ANA−, RF−, anti‐CCP Ab− |
Improved after short‐term GC and NSAIDs |
| Case 3 | 20s | F |
mRNA‐1273 Moderna (first dose) |
10 days |
Aseptic meningitis, necrotizing lymphadenitis, hair loss, chilblain lupus (SLEa) |
120 | 4.3 |
ANA 1:1280, anti‐Ro Ab > 240 U/ml, anti‐La Ab > 320 U/ml, direct coombs test+ |
Improved after medium‐dose GC, HCQ, and NSAIDs |
| Case 4 | 60s | F |
ChAdOx1‐S AstraZeneca (first dose) |
3 days |
Bilateral shoulder stiffness and pain (PMR) |
98 | 3.0 |
ANA 1:160, anti‐dsDNA Ab 18 IU/ml, RF−, anti‐CCP Ab− |
Improved after low‐dose GC and MTX |
Abbreviations: Ab, antibody; ANA, antinuclear antibody; CCP, cyclic citrullinated peptide; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; GC, glucocorticoid; HCQ, hydroxychloroquine; MTX, methotrexate; NSAIDs, nonsteroidal anti‐inflammatory drugs; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics; SpA, spondyloarthritis; SSZ, sulfasalazine; +, positive; −, negative.
We diagnosed this patient with SLE based on the SLICC criteria.